Stable hypoxia inducible factor-1 alpha and method of use
CA 2340328 C · Owner: The Johns Hopkins University School Of Medicine · Inventors: Semenza, Gregg L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Substantially purified stable human hypoxia-inducible factor-1.alpha. (sHIF- 1alpha) proteins and polynucleotides encoding stable human hypoxia-inducible factor-1.alpha. proteins are provided. A method is provided for treating a hypoxia-related tissue damage in a subject by administering to the subject a therapeutically effective amount of an sHIF- 1alpha protein or a nucleic acid encoding a stable HIF-1alpha protein. Formulations are provided for the administration of stable human hypoxia inducible factor-1.alpha. (HIF-1alpha) polypeptide or a polynucleotide encoding stable human hypoxia inducible factor-1alpha (HIF- 1alpha) to a patient having or at risk of having hypoxia- of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 25, 1999 and granted June 21, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 25, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 25, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.